Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
YESAccepted90% confidencemanual-chat-review
Will the results be positive?
Immunovant publicly described the Phase 2b CIDP study as positive, highlighting week-12 improvement in adjusted INCAT and strong responder rates in patients with deeper IgG lowering.
Found Apr 4, 2026, 8:52 PMOutcome date May 29, 2025, 12:00 AMReviewed Apr 6, 2026, 1:37 PM
NO_DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
Public disclosure exists, but it is not an overall Phase 2 readout. Sponsor materials describe only initial/pooled Period 1 CIDP data, while the trial’s primary endpoint is Period 2 relapse-free status at Week 36. The study was still ongoing/active, so the exact trial cannot yet be labeled overall positive or negative.
Found Apr 3, 2026, 5:20 PMReviewed Apr 3, 2026, 5:20 PM
Sponsorimmunovant.comMar 19, 2025, 12:00 AM
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis and CIDP Studies
For the CIDP Phase 2b study, the release says only initial Period 1 pooled data were available; the study was ongoing, not yet unblinded, and no data were available for the primary endpoint at the end of Period 2.
Sponsorimmunovant.comMay 8, 2025, 12:00 AM
Immunovant SEC filing for quarter ended March 31, 2025
The company states it announced initial results from Period 1 of the Phase 2b CIDP trial; Period 1 was a non-placebo-controlled run-in, with meaningful improvements described only in pooled dose cohorts.
ClinicalTrialsclinicaltrials.gov
Study Details | NCT05581199 | To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
ClinicalTrials.gov listed NCT05581199 as Active, not recruiting, with estimated primary completion in January 2026, supporting that a final primary-endpoint readout was not yet complete at the time of the public update.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
Public readout exists, but it was only an initial Period 1 pooled update. The sponsor framed CIDP data as positive/meaningful, yet also stated the study was ongoing, unblinded Period 2 data were unavailable, and the primary endpoint is the Week 36 relapse-free result. That makes the exact trial’s overall outcome incomplete.
Found Apr 2, 2026, 5:14 PMReviewed Apr 3, 2026, 4:48 PM
NO_DECISIONDismissed94% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
Public CIDP data were only an initial Period 1 readout. Although the sponsor called those results positive, the exact Phase 2b trial remains ongoing, unblinded for Period 2, and the primary endpoint (relapse-free at Week 36) has not been reported. That is not enough for an overall trial-level positive/negative call.
Found Mar 31, 2026, 9:44 PMReviewed Apr 1, 2026, 6:34 AM
NO_DECISIONDismissed94% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No overall Phase 2 readout is publicly available for this exact trial. The sponsor disclosed only initial Period 1 CIDP data and explicitly said the study was still ongoing, still blinded for the primary endpoint period, and that no Period 2 primary-endpoint data were available. ClinicalTrials.gov also continued to list NCT05581199 as active and not recruiting with estimated primary completion in January 2026. Because the public evidence is partial, pooled, and not the primary endpoint readout for this exact study, the trial cannot be classified overall as positive or negative.
Found Mar 30, 2026, 4:36 AMReviewed Mar 30, 2026, 7:04 AM
Sponsorimmunovant.comMar 19, 2025, 12:00 AM
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Immunovant said it reported topline results from Phase 3 MG and only initial results from Period 1 of the Phase 2b CIDP study. In the CIDP section, the company stated that the primary endpoint is the percentage of participants who remain relapse-free at Week 36 at the end of Period 2, and that the study is ongoing and has not yet been unblinded. It further stated that only pooled Period 1 data were currently available and that no data were available for the primary endpoint at the end of Period 2.
ClinicalTrialsclinicaltrials.gov
Study Details | NCT05581199 | To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
ClinicalTrials.gov lists NCT05581199 as a Phase 2b study of batoclimab in active CIDP and shows the study as Active, not recruiting, with estimated primary completion in January 2026.
Sponsord1io3yog0oux5.cloudfront.netMay 29, 2025, 12:00 AM
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
In its later corporate update, Immunovant again described the CIDP disclosure as initial results from week 12 of the Phase 2b CIDP study, reporting a mean improvement in adjusted INCAT disability score and an 84% responder rate in patients with greater than 70% IgG lowering.